Sobi entered into an exclusive license agreement with ADC Therapeutics SA to develop and commercialise loncastuximab tesirine for use in haematology and other indications of large unmet medical need in Europe and most international markets. It is already approved in the US and under regulatory review in Europe with a decision anticipated in 2023.
Article published on startupticker.ch